Psyched Wellness Attracts Major Investment
Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff
Read moreJeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff
Read moreAfter more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning had a major announcement. The
Read morePsyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company,
Read morePsyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract of Amanita Muscaria. The company
Read morePsyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity preclinical study. The study was
Read morePsyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom extract formulation. The company this
Read moreStarting off the short Canadian trading week this week on the Daily Dive is that of Jeff Stevens, CEO of
Read morePsyched Wellness (CSE: PSYC) this morning had a brief announcement. Within, the company revealed that it has entered into a
Read morePsyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing studies. The firm has initiated
Read morePsyched Wellness (CSE: PSYC) has begun the process of protecting its intellectual property. The firm this morning announced that it
Read more